Delaware Chapter of the American College of Cardiology

Join us for the ACC Delaware Chapter Meeting: ACC by the Sea for engaging live education sessions from local, regional, and national experts with Q&A real-time. The educational meeting includes topics of cardio obstetrics, lipids, amyloid, etc., and a chapter update from our Governor Dr. Vinay Hosmane. Participation in this event will earn CME/CNE/and MOC. We look forward to seeing you (IN-PERSON) September 12 - 13, 2025!

For more Information and Register: Delaware ACC By the Sea: 2025 Chapter Meeting

Delaware Chapter of the American College of Cardiology

Our purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments.

ACC Live Courses

For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

Latest in Cardiology from ACC.org

New Research Underscores Benefits of Influenza and RSV Vaccinations
Findings from the DANFLU-2 and GALFLU trials on high-dose influenza vaccines and the DAN-RSV trial evaluating a bivalent respiratory syncytial virus (RSV) prefusion F proteinâ€“based vaccine add to the growing body of evidence surrounding the benefits of influenza and RSV vaccinations in preventing hospitalizations.
ALONE-AF, CUVIA-PRR and BEAT-PAROX-AF Hot Line Trials Offer New Data on AFib Treatments
Discontinuing oral anticoagulant (OAC) therapy in patients with no documented atrial arrhythmia recurrence one year after catheter ablation for atrial fibrillation (AFib) resulted in a lower risk for the composite of stroke, systemic embolism and major bleeding compared with continuing direct oral anticoagulant therapy...
DAPT-SHOCK-AMI: IV Cangrelor vs. Crushed Ticagrelor in Patients With Acute MI and Cardiogenic Shock
Compared with crushed ticagrelor, intravenous (IV) cangrelor provided immediate and effective platelet inhibition with no increase in major bleeding and lower mortality rates in patients with acute myocardial infarction (MI) and cardiogenic shock.
New Studies Explore Early Aspirin Withdrawal and Tailored Antiplatelet Strategies Following PCI
Early withdrawal of aspirin following successful PCI for acute coronary syndrome and in low-risk patients following an acute myocardial infarction (MI) was the focus of two separate hot line trials presented at ESC Congress 2025.
DUAL-ACS: 12-Month vs. 3-Month DAPT Following Acute MI
Findings from the DUAL-ACS trial presented at ESC Congress 2025 suggest that three months of dual antiplatelet therapy (DAPT) following an acute myocardial infarction (MI) has the potential for better survival and lower bleeding rates compared with 12 months of DAPT.